| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008010543 |
| P356 | DOI | 10.1038/NRRHEUM.2012.97 |
| P698 | PubMed publication ID | 22825731 |
| P50 | author | Carlo Salvarani | Q37835033 |
| Nicolo Pipitone | Q92155214 | ||
| Annibale Versari | Q100377798 | ||
| Gene G Hunder | Q114429049 | ||
| P2860 | cites work | A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. | Q33905501 |
| Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients | Q33993390 | ||
| Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease | Q34184474 | ||
| Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies | Q34203876 | ||
| The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis | Q34227003 | ||
| Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis | Q34272134 | ||
| Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients | Q34283592 | ||
| Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial | Q34346251 | ||
| Polymyalgia rheumatica and giant-cell arteritis. | Q34525621 | ||
| Large-vessel involvement in giant cell arteritis | Q34563313 | ||
| A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis | Q34587431 | ||
| Skip lesions in temporal arteritis | Q34746198 | ||
| Prognosis in giant-cell arteritis | Q34776865 | ||
| Response to 'Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial'. | Q35092876 | ||
| Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy | Q35150781 | ||
| Stopping steroids in polymyalgia rheumatica and giant cell arteritis | Q35167736 | ||
| Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. | Q35200712 | ||
| EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). | Q35552286 | ||
| A disease activity score for polymyalgia rheumatica | Q35553332 | ||
| Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis | Q35605540 | ||
| Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis | Q35636876 | ||
| Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells | Q35787897 | ||
| 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Q35819013 | ||
| Are steroids alone sufficient for the treatment of giant cell arteritis? | Q36109383 | ||
| Vascular dendritic cells in giant cell arteritis | Q36388695 | ||
| Long-term outcome of giant cell arteritis. | Q36543232 | ||
| Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences | Q36688501 | ||
| Vasculitis: a collection of pearls and myths | Q37013671 | ||
| Improving therapeutic options for patients with giant cell arteritis. | Q37087253 | ||
| Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? | Q37088750 | ||
| Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. | Q37091479 | ||
| EULAR recommendations for the management of large vessel vasculitis. | Q37138796 | ||
| The role of infectious agents in the pathogenesis of vasculitis. | Q37333111 | ||
| Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). | Q24514780 | ||
| Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis | Q28168182 | ||
| Antiplatelet and anticoagulant therapy in patients with giant cell arteritis | Q28200579 | ||
| Color duplex ultrasonography in the diagnosis of temporal arteritis | Q28253592 | ||
| Role of ultrasonography in the diagnosis of temporal arteritis | Q30987760 | ||
| Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. | Q31009567 | ||
| Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis | Q31120357 | ||
| Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial | Q31933661 | ||
| Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients | Q33264062 | ||
| Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis | Q33339299 | ||
| Disease pattern in cranial and large-vessel giant cell arteritis | Q33534693 | ||
| The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis | Q33538316 | ||
| An evaluation of criteria for polymyalgia rheumatica | Q33552073 | ||
| Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study | Q33556408 | ||
| Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. | Q33561938 | ||
| Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? | Q33578847 | ||
| Arterial wall injury in giant cell arteritis | Q33633304 | ||
| Th17 and Th1 T-cell responses in giant cell arteritis | Q33723160 | ||
| Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group | Q33885156 | ||
| Vessel-specific Toll-like receptor profiles in human medium and large arteries | Q37357843 | ||
| Epidemiology of giant cell arteritis and polymyalgia rheumatica | Q37605653 | ||
| Giant cell arteritis in Asians: a comparative study | Q37768278 | ||
| Delays in recognition and management of giant cell arteritis: results from a retrospective audit | Q37810491 | ||
| The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern | Q38508719 | ||
| Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study | Q38787301 | ||
| The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee | Q39349289 | ||
| Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis | Q40521781 | ||
| Giant cell arteritis without clinically evident vascular involvement in a defined population | Q40536237 | ||
| Giant cell arteritis manifesting as chronic cough and fever of unknown origin | Q40644016 | ||
| Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment | Q40846409 | ||
| Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin | Q40849980 | ||
| Wegener's granulomatosis associated with vasculitis of the temporal artery: report of five cases | Q40870666 | ||
| Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months | Q41210439 | ||
| Gelatinase expression and proteolytic activity in giant-cell arteritis | Q41348284 | ||
| The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration | Q41503475 | ||
| A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects | Q42522648 | ||
| Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica | Q42919689 | ||
| BSR and BHPR guidelines for the management of polymyalgia rheumatica | Q43243185 | ||
| Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study | Q43589677 | ||
| Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis | Q43629680 | ||
| Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. | Q43709533 | ||
| A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). | Q43752804 | ||
| Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls | Q43800168 | ||
| Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: a magnetic resonance imaging study | Q43831068 | ||
| Non-complicated Horton's disease: initial treatment with methylprednisolone 500 mg/day bolus for three days followed by 20 mg/day prednisone-equivalent. Evaluation of 15 patients | Q43870444 | ||
| A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis | Q44062281 | ||
| Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study | Q44326336 | ||
| Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. | Q44388093 | ||
| Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes | Q44616879 | ||
| Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis | Q44695993 | ||
| Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. | Q44756545 | ||
| Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica | Q44768557 | ||
| Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial | Q45091780 | ||
| A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease? | Q45294877 | ||
| The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease | Q45300713 | ||
| Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. | Q46428522 | ||
| Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. | Q46724783 | ||
| Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation | Q47971516 | ||
| Patient-reported outcomes in polymyalgia rheumatica | Q48014934 | ||
| Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis | Q48486373 | ||
| Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. | Q50590140 | ||
| Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes. | Q50895197 | ||
| Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. | Q50929199 | ||
| BSR and BHPR guidelines for the management of giant cell arteritis. | Q51706743 | ||
| Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?. | Q52034402 | ||
| Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study | Q52877882 | ||
| The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. | Q53605993 | ||
| Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. | Q53650756 | ||
| Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. | Q54380232 | ||
| Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. | Q54774036 | ||
| Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. | Q55037958 | ||
| Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? | Q55066905 | ||
| Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica | Q57002708 | ||
| Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes | Q57279273 | ||
| Contribution of MHC class I region to genetic susceptibility for giant cell arteritis | Q57307112 | ||
| Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial | Q57786353 | ||
| Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis | Q58621638 | ||
| Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial | Q61698813 | ||
| Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis | Q61914206 | ||
| Development of Ischemic Complications in Patients With Giant Cell Arteritis Presenting With Apparently Isolated Polymyalgia Rheumatica | Q61914210 | ||
| Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. | Q64892284 | ||
| Musculoskeletal Manifestations of Bacterial Endocarditis | Q66839716 | ||
| Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis | Q67857730 | ||
| C-Reactive Protein in Giant Cell (Cranial, Temporal) Artentis | Q70805834 | ||
| Long-term follow-up of polymyalgia rheumatica: evidence for synovitis | Q71372561 | ||
| Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica | Q72857241 | ||
| Proximal Bursitis in Active Polymyalgia Rheumatica | Q73491578 | ||
| Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis | Q73834934 | ||
| Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate | Q73880348 | ||
| Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study | Q73899195 | ||
| IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis | Q74249517 | ||
| Ocular manifestations of giant cell arteritis | Q74481024 | ||
| Polymyalgia rheumatica: a disorder of extraarticular synovial structures? | Q74631173 | ||
| Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study | Q74776739 | ||
| Polymyalgia rheumatica and biopsy-proven giant cell arteritis exhibit different HLA-DRB1* associations | Q75248329 | ||
| Treatment of longstanding active giant cell arteritis with infliximab: report of four cases | Q77406869 | ||
| Polymyalgia rheumatica and giant-cell arteritis | Q78686015 | ||
| Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years | Q79365081 | ||
| Giant cell arteritis: Involvement of intracranial arteries | Q79398040 | ||
| Ischemic optic neuropathies | Q79946673 | ||
| Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis | Q79948743 | ||
| Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases | Q80142311 | ||
| Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial | Q80242517 | ||
| Cervical interspinous bursitis in active polymyalgia rheumatica | Q80523086 | ||
| Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging | Q80955761 | ||
| Polymyalgia rheumatica | Q81021951 | ||
| PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis | Q81377163 | ||
| Polymyalgia rheumatica and giant-cell arteritis | Q81668995 | ||
| Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling | Q81926568 | ||
| Tocilizumab: a novel therapy for patients with large-vessel vasculitis | Q82461505 | ||
| Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series | Q83226683 | ||
| More or less rituximab? Biology and clinic, regulators and researchers | Q83499653 | ||
| Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica | Q83572529 | ||
| Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica | Q84150643 | ||
| Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis | Q85001806 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polymyalgia rheumatica | Q1752891 |
| P304 | page(s) | 509-521 | |
| P577 | publication date | 2012-07-24 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Clinical features of polymyalgia rheumatica and giant cell arteritis | |
| P478 | volume | 8 |
| Q37205901 | A Retrospective Study of Chinese Patients With Giant Cell Arteritis (GCA): Clinical Features and Factors Associated With Severe Ischemic Manifestations |
| Q34153209 | A rare case of temporal arteritis with rheumatoid arthritis and interstitial lung disease mimicking pulpo-periodontal pathology |
| Q42394276 | Bilateral vertebral artery occlusion without headache in giant cell arteritis |
| Q52893205 | Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. |
| Q51033475 | Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. |
| Q90911186 | Clinical Factors Associated with Time-Specific Distribution of 18F-Fluorodeoxyglucose in Large-Vessel Vasculitis |
| Q27005821 | Clinical practice. Giant-cell arteritis and polymyalgia rheumatica |
| Q53082949 | Comment on: FDG PET in the early diagnosis of large-vessel vasculitis. |
| Q30355568 | Cutaneous nocardiosis manifesting as a frontal mass in a patient with giant cell arteritis |
| Q39006910 | Diagnosis and clinical features of common optic neuropathies |
| Q51092032 | Early onset polymyalgia rheumatica: two rare cases under age of 50. |
| Q53118262 | Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. |
| Q36152152 | Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study |
| Q38583653 | Giant Cell Arteritis of the Female Genital Tract With Occult Temporal Arteritis and Marginal Zone Lymphoma Harboring Novel 20q Deletion: A Case Report and Literature Review. |
| Q38560322 | Giant Cell Arteritis: Beyond Corticosteroids |
| Q36992669 | Giant Cell Arteritis: From Pathogenesis to Therapeutic Management. |
| Q38919828 | Giant cell arteritis: ophthalmic manifestations of a systemic disease |
| Q92141877 | Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab |
| Q40065347 | Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis |
| Q47182000 | Identification of Herpes Zoster-Associated Temporal Arteritis Among Cases of Giant Cell Arteritis |
| Q52659244 | Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. |
| Q36484399 | Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity |
| Q47715350 | Increased expression of interleukin-22 in patients with giant cell arteritis. |
| Q54310546 | Leg ulcers associated with giant cell arteritis relapse. |
| Q41117637 | MMP-3 can distinguish isolated PMR from PMR with GCA: A retrospective study regarding PMR and GCA in Japan |
| Q61813381 | Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases |
| Q53355647 | MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. |
| Q87300776 | Pericardial effusion and giant cell arteritis |
| Q53073312 | Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. |
| Q39200766 | Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). |
| Q36150929 | Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients |
| Q88646789 | Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK |
| Q60045369 | Simultaneous bilateral posterior ischemic optic neuropathy secondary to giant cell arteritis: a case presentation and review of the literature |
| Q64279075 | Spontaneous remission of giant cell arteritis: possible association with a preceding acute respiratory infection and seropositivity to antibodies |
| Q64238813 | Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes |
| Q55439546 | The Utility of Color Duplex Ultrasonography in the Diagnosis of Giant Cell Arteritis: A Prospective, Masked Study. (An American Ophthalmological Society Thesis). |
| Q53066544 | The process from symptom onset to rheumatology clinic in polymyalgia rheumatica. |
| Q28069460 | The role of toll like receptors in giant cell arteritis |
| Q39275487 | The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. |
Search more.